Home > Press > Nano Labs Shareholder Update
Abstract:
Nano Labs Corp. (OTCQB: CTLE) is pleased to provide the following update to shareholders regarding the Company direction and vision for 2014.
Dear Shareholders,
Over the past 18 months the company has worked with Dr. Castano, our team of researchers, designers, and engineers on creating a portfolio of advanced nano technology that will provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare.
Since entering into an Asset Purchase Agreement with Dr. Victor Castano on October 10, 2012 the company has followed Dr. Castano's lead and filed Intellectual Patents after reviewing several of Dr. Castano's publications. The first product identified by the company to take to market was the Nano Coatings technology.
The Nano Coatings were produced in the laboratory environment and tested under ASTM and Underwriters Laboratory protocol by several testing facilities. The company has also approached several manufactures to produce the product under license over the past 18 months. However, the company experienced consistent problems with the manufacturing of the Nano Coatings as it applies to developing several other coatings applications for uses in the Nano Nail Polish and LED system.
The Board of Directors has determined that the outstanding manufacturing issues to be resolved with the coatings technology were extensive and problematic, and it is in the best interest of the company to pursue our other opportunities such as Polec Industries and industry sectors not related to the Nano Coatings at this time.
The Board of Directors agreed that the consummation of the Asset Purchase Agreement is not in the best interests of the Company or its shareholders in light of certain difficulties pertaining to the intellectual property, testing, and the production of the Nano Coating Technology and other products provided by Dr. Castano using his Nano Coating Technology.
The Company has determined and agreed with Dr. Castano that the Asset Purchase Agreement should be rescinded (the "Rescission") and that all right, title and interest in and to the Nano Coating Technology and products publications be returned to Dr. Castano. Dr. Castano has accepted to rescind the Asset Purchase Agreement and return 101 million common shares of Nano labs Corp to the Company for cancelation.
The Rescission Agreement was signed on March 4th, 2014 with Dr. Castano, and the Company received the resignation of Dr. Victor Castano as Chairman and Chief Technology Officer on the same day.
We continue to follow our core strategy of developing a diversified investment of nanotechnologies for our shareholders in Nano Labs. The Company will continue negotiations with Polec Industries and other potential opportunities currently under review. The Company is also in the process of interviewing several potential high-level candidates to replace Dr. Castano as Chief Research and Innovations Officer of Nano Labs and continue move the company in the direction to generate revenues in 2014.
We are working to create products and materials that come with the satisfying investment benefit of making our industries stronger, our economies healthier, and our environment safer. The company plans to update our shareholders in the weeks to come as to the direction the company will take in 2014.
Respectfully on behalf of the Board,
Mr. Bernardo Camacho Chavarria
President, Nano Labs
####
About Nano Labs Corp.
Nano Labs Corp. (CTLE) is a nanotechnology company whose research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.
Forward-looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.
For more information, please click here
Contacts:
Bernardo Camacho Chavarria
President
1 (888) 806-2315
Copyright © Nano Labs Corp.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over 14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Appointments/Promotions/New hires/Resignations/Deaths
Leibniz Prize winner Professor Dr. Oliver G. Schmidt moves to Chemnitz University of Technology: President Professor Dr. Gerd Strohmeier refers to an 'absolute top transfer' September 10th, 2021
JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021
The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020
Energy
KAIST researchers introduce new and improved, next-generation perovskite solar cell November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Groundbreaking precision in single-molecule optoelectronics August 16th, 2024
Development of zinc oxide nanopagoda array photoelectrode: photoelectrochemical water-splitting hydrogen production January 12th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||